-
1
المؤلفون: Florence Granel-Brocard, Alain Dupuy, D. Legoupil, Jean-Jacques Grob, Marie Beylot-Barry, Marie-Thérèse Leccia, Jean-Philippe Arnault, Florence Brunet-Possenti, A. Bardet, Pierre-Emmanuel Stoebner, Céleste Lebbe, Stéphane Dalle, Eve Maubec, Clara Allayous, Isabelle Borget, Bernard Guillot, Brigitte Dréno, Julie DeQuatrebarbes, Philippe Saiag, Laurent Mortier, Marguerite Kandel, Sophie Dalac, Caroline Dutriaux, Thierry Lesimple, Stefan Michiels, Henri Montaudié, François Aubin
المساهمون: Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut Gustave Roussy (IGR), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de biostatistique et d'épidémiologie (SBE), Direction de la recherche clinique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 (ONCO-THAI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Groupe hospitalier Saint-André, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire [Grenoble] (CHU), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Hôpital Ambroise Paré [AP-HP], Centre Hospitalier Universitaire de Nice (CHU Nice), Service de dermatologie [CHU d'Amiens-Picardie], CHU Amiens-Picardie, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de dermatologie, vénéreologie et cancérologie cutanée [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], Service de dermatologie [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], CRLCC Eugène Marquis (CRLCC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Avicennes University Hospital, Service de Dermatologie et Allergologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Service de Dermatologie [Rennes] = Dermatology [Rennes], CHU Pontchaillou [Rennes], Service de dermatologie [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Oncostat (U1018 (Équipe 2)), Institut Gustave Roussy (IGR)-Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Centre Léon Bérard [Lyon], AP-HP. Université Paris Saclay, Amgen Pfizer Merck Novartis Roche Janssen Biotech Meso Scale Diagnostics, MSD Array BioPharma Takeda Pharmaceutical Company Sanofi Pasteur British Microcirculation Society, BMS Institut National Du Cancer, INCa: DOC 16‐009, This work was supported by the French National Cancer Institute (DOC 16‐009)., Stéphane Dalle reports institutional research funding Roche, institutional research funding and nonfinancial support from Bristol‐Myers Squibb (BMS), and an immediate family member who is employed by Sanofi and owns stock or other ownership interest in the company. Aurélie Bardet was employed by Roche and held stock and other ownership interest in the company until March of 2018. Clara Allayous reports nonfinancial support from BMS, Amgen, and Roche outside the submitted work. Laurent Mortier reports personal fees and nonfinancial support from Roche, Novartis, BMS, and Merck Sharp & Dohme (MSD) outside the submitted work. Caroline Dutriaux reports personal fees from Roche, BMS, Novartis, MSD, and Pierre Fabre Laboratories outside the submitted work. Philippe Saiag reports research funding and personal fees from Roche, grants, personal fees, and nonfinancial support from BMS, MSD, Novartis, and Pierre Fabre Laboratories, and personal fees from Array, Sanofi, and Merck, all outside the submitted work. Henri Montaudié reports institutional research funding from LeoPharma, institutional research funding, personal fees, and nonfinancial support from BMS, personal fees from Pierre Fabre Laboratories and MSD, and nonfinancial support from Novartis, all outside the submitted work. Jean‐Phillipe Arnault reports institutional research funding and personal fees from BMS and institutional research funding from Novartis outside the submitted work. Jean‐Jacques Grob reports personal fees and nonfinancial support from BMS, Roche, MSD, Novartis, Merck, Amgen, Pierre Fabre Laboratories, Sanofi, and Pfizer and nonfinancial support from Amgen, all outside the submitted work. Julie De Quatrebarbes reports nonfinancial support from BMS, MSD, and Janssen outside the submitted work. Thierry Lesimple reports research funding and personal fees from Roche and personal fees from BMS, MSD, Novartis, Pierre Fabre Laboratories, and Incyte, all outside the submitted work. François Aubin reports personal fees and nonfinancial support from Novartis, MSD, and Roche outside the submitted work. Eve Maubec reports grants, personal fees, and nonfinancial support from MSD, personal fees from Sanofi and Novartis, personal fees and nonfinancial support from BMS, and nonfinancial support from Pierre Fabre Laboratories, all outside the submitted work. Stefan Michiels reports personal fees from IDDI Belgium, Janssen Cilag France, Hexal, Johnson & Johnson, Ipsen, Genticel, Mabxience, Steba, IQVIA, Roche, Sensorion, Biophytis, and Servier, all outside the submitted work. Céleste Lebbe reports institutional research funding, personal fees, and nonfinancial support from BMS, institutional funding and personal fees from Roche, personal fees and nonfinancial support from MSD, and personal fees from Aventis, Novartis, Amgen, Pierre Fabre Laboratories, Pfizer, and Incyte, all outside the submitted work. Isabelle Borget reports research funding from the BMS Foundation during the course of the study and personal fees from Roche, Janssen, CSC Behring, Novartis, and Takeda outside the submitted work. The remaining authors made no disclosures., Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Hôpital de la Timone [CHU - APHM] (TIMONE)-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)
المصدر: Cancer
Cancer, 2020, 126 (3), pp.611-618. ⟨10.1002/cncr.32554⟩
Cancer, Wiley, 2020, 126 (3), pp.611-618. ⟨10.1002/cncr.32554⟩مصطلحات موضوعية: Male, Cancer Research, MESH: Adolescent, Adult, Aged, 80 and over, Cohort Studies, Disease Progression, Female, France / epidemiology, Humans, Disease, Clinical practice, Targeted therapy, 0302 clinical medicine, Second line, Quality of life, Advanced disease, Medicine, Molecular Targeted Therapy, Prospective Studies, 030212 general & internal medicine, Neoplasm Metastasis, Melanoma, MESH: Immunotherapy, Melanoma / epidemiology, Melanoma / immunology, Melanoma / pathology, Melanoma / therapy, MESH: Middle Aged, Neoplasms, Second Primary / epidemiology, Young Adult, Real-life, Neoplasms, Second Primary, Middle Aged, 3. Good health, Survival Rate, Oncology, 030220 oncology & carcinogenesis, Cohort, France, Immunotherapy, medicine.medical_specialty, Adolescent, Metastatic melanoma, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, Internal medicine, In real life, Survival rate, Aged, business.industry, MESH: Neoplasms, Second Primary / immunology, Neoplasms, Second Primary / pathology, Quality of Life, business, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e7cc27d9b011eb68b46c2a487331edaTest
https://doi.org/10.1002/cncr.32554Test -
2
المؤلفون: Steen Rosthøj, Birgitte Klug Albertsen, Henrik Daa Schrøder, Karen Schow Jensen, Kjeld Schmiegelow, Alina Zalounina Falborg, Peter Vedsted, Michael Callesen
المصدر: Jensen, K S, Klug Albertsen, B, Schrøder, H, Zalounina Falborg, A, Schmiegelow, K, Rosthøj, S, Callesen, M T & Vedsted, P 2021, ' Health care utilisation preceding relapse or second malignant neoplasm after childhood acute lymphoblastic leukaemia : a population-based matched cohort study ', BMJ Open, vol. 11, no. 8, e050285 . https://doi.org/10.1136/bmjopen-2021-050285Test
BMJ Open, Vol 11, Iss 8 (2021)
BMJ Open
Jensen, K S, Klug Albertsen, B, Schrøder, H, Zalounina Falborg, A, Schmiegelow, K, Rosthøj, S, Callesen, M T & Vedsted, P 2021, ' Health care utilisation preceding relapse or second malignant neoplasm after childhood acute lymphoblastic leukaemia : A population-based matched cohort study ', BMJ Open, vol. 11, no. 8, e050285 . https://doi.org/10.1136/bmjopen-2021-050285Test
Jensen, K S, Klug Albertsen, B, Schrøder, H, Zalounina Falborg, A, Schmiegelow, K, Rosthøj, S, Callesen, M T & Vedsted, P 2021, ' Health care utilisation preceding relapse or second malignant neoplasm after childhood acute lymphoblastic leukaemia : A population-based matched cohort study ', BMJ Open, vol. 11, no. 8, e050285, pp. e050285 . https://doi.org/10.1136/bmjopen-2021-050285Testمصطلحات موضوعية: Pediatrics, medicine.medical_specialty, Precursor Cell Lymphoblastic Leukemia-Lymphoma/epidemiology, Population based, Cohort Studies, primary care, Risk groups, Matched cohort, Recurrence, Health care, Medicine, Humans, Child, Childhood all, business.industry, First remission, Neoplasms, Second Primary, General Medicine, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Patient Acceptance of Health Care, paediatric oncology, leukaemia, Lymphoblastic leukaemia, Neoplasms, Second Primary/epidemiology, business, Cohort study, Haematology (Incl Blood Transfusion)
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a235f763626a0dd438a9260b5bd547bTest
https://vbn.aau.dk/ws/files/441888781/Jensen_et_al_2021_Health_care_utilisation_preceding_relapse_or_second_malignant_neoplasm_after_childhood_acute_lymphoblastic_leukaemia.pdfTest -
3
المؤلفون: Nicolas Waespe, Marc Ansari, Jean-Pierre Bourquin, Maja Beck-Popovic, Fabiën N. Belle, Jochen Rössler, Shelagh Redmond, Ben D. Spycher, Nicolas von der Weid, Jeanette Greiner, Katrin Scheinemann, Claudia E. Kuehni, Christina Schindera, Freimut H. Schilling, Pierluigi Brazzola
المساهمون: University of Zurich, Kuehni, Claudia E
المصدر: European journal of cancer, Vol. 145 (2021) pp. 71-80
Waespe, Nicolas; Belle, Fabiën N.; Redmond, Shelagh; Schindera, Christina; Spycher, Ben D.; Rössler, Jochen; Ansari, Marc; Kuehni, Claudia E. (2021). Cancer predisposition syndromes as a risk factor for early second primary neoplasms after childhood cancer-A national cohort study. European journal of cancer, 145, pp. 71-80. Elsevier 10.1016/j.ejca.2020.11.042 <http://dx.doi.org/10.1016/j.ejca.2020.11.042Test>مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, Genetic testing, Swiss childhood cancer registry, Cancer survivors, Second primary neoplasms, Pediatrics, 0302 clinical medicine, Cancer Survivors, Neoplasms, Second Primary / diagnosis, Risk Factors, Adolescent medicine, Neoplasms, Medicine, Cumulative incidence, 1306 Cancer Research, Registries, 610 Medicine & health, Child, education.field_of_study, ddc:618, Neoplastic Syndromes, Hereditary / epidemiology, Incidence (epidemiology), Incidence, Hazard ratio, Hematopoietic Stem Cell Transplantation, Age Factors, Neoplasms, Second Primary, Neoplasms, Second Primary / epidemiology, Oncology, 030220 oncology & carcinogenesis, Early detection of cancer, Child, Preschool, Neoplastic Syndromes, Hereditary / diagnosis, Female, 2730 Oncology, Switzerland, 360 Social problems & social services, Cohort study, medicine.medical_specialty, Adolescent, Population, Antineoplastic Agents, Risk Assessment, Switzerland / epidemiology, 03 medical and health sciences, Young Adult, Neoplastic Syndromes, Hereditary, Internal medicine, Humans, Risk factor, education, Radiotherapy / adverse effects, Genetic counselling, Radiotherapy, business.industry, Hereditary neoplastic syndromes, Antineoplastic Agents / adverse effects, Hematopoietic Stem Cell Transplantation / adverse effects, Infant, Newborn, Cancer, Infant, medicine.disease, Transplantation, 030104 developmental biology, 10036 Medical Clinic, business
وصف الملف: PIIS0959804920313794.pdf - application/pdf; application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cacba93b3aead1ce124526b0cc6cbddaTest
https://doi.org/10.5167/uzh-213020Test -
4
المؤلفون: Teepen, J.C., Kremer, L.C., Heiden-van der Loo, M. van der, Tissing, W.J., Pal, H.J. van der, Heuvel-Eibrink, M.M. van den, Loonen, J.J., Louwerens, M., Versluys, B., Dulmen-den Broeder, E. van, Visser, O., Maduro, J.H., Leeuwen, F.E. van, Ronckers, C.M., Bresters, D., Batenburg, L., Veening, M., Huizinga, G., Steeg, L. van der, Jaspers, M., Vries, A. de, Aleman, B.M.P., Caron, H.N., Grootenhuis, M.A., Hartogh, J.G. den, Hollema, N., Neggers, S.J.C.M.M., Postma, A., Ridder-Sluiter, J.G. de, Rutgers, E.J.T., DCOG-LATER Study Grp
المساهمون: Graduate School, CCA - Cancer Treatment and Quality of Life, ARD - Amsterdam Reproduction and Development, Paediatric Oncology, Child and Adolescent Psychiatry & Psychosocial Care, APH - Mental Health, APH - Methodology, Epidemiology and Data Science, Amsterdam Reproduction & Development (AR&D), Pediatric surgery, CCA - Cancer Treatment and quality of life, Pediatrics, Internal Medicine, Guided Treatment in Optimal Selected Cancer Patients (GUTS)
المصدر: Cancer causes & control. Springer Netherlands
Cancer Causes & Control, 30, 9, pp. 909-922
Cancer Causes and Control, 30(9), 909. Springer Netherlands
Cancer Causes and Control, 30(9), 909-922. Springer Netherlands
Cancer Causes & Control, 30(9), 909-922. Springer Netherlands
Cancer Causes & Control, 30, 909-922
Teepen, J C, Kremer, L C, van der Heiden-van der Loo, M, Tissing, W J, van der Pal, H J, van den Heuvel-Eibrink, M M, Loonen, J J, Louwerens, M, Versluys, B, van Dulmen-den Broeder, E, Visser, O, Maduro, J H, van Leeuwen, F E, Ronckers, C M & the DCOG-LATER Study Group 2019, ' Clinical characteristics and survival patterns of subsequent sarcoma, breast cancer, and melanoma after childhood cancer in the DCOG-LATER cohort ', Cancer Causes and Control, vol. 30, no. 9, pp. 909-922 . https://doi.org/10.1007/s10552-019-01204-zTest
Cancer causes & control, 30(9), 909-922. SPRINGER
Cancer Causes and Control, 30(9), 909-922. SPRINGERمصطلحات موضوعية: Oncology, Male, Cancer Research, Skin Neoplasms, PROGNOSIS, Survival, Epidemiology, medicine.medical_treatment, Childhood cancer survivors, Cohort Studies, SOFT-TISSUE SARCOMAS, 0302 clinical medicine, Cancer Survivors, Neoplasms, Medicine, 030212 general & internal medicine, Sarcoma/epidemiology, Child, 2ND PRIMARY, Melanoma, Netherlands, RISK, education.field_of_study, Breast Neoplasms/epidemiology, Hazard ratio, Neoplasms, Second Primary, Sarcoma, 030220 oncology & carcinogenesis, HEALTH OUTCOMES, Skin Neoplasms/epidemiology, Female, Adult, medicine.medical_specialty, Population, Long-term complications, Second Primary/epidemiology, Breast Neoplasms, Melanoma/epidemiology, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], 03 medical and health sciences, Breast cancer, All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, Internal medicine, PRIMARY THYROID-CANCER, Journal Article, Humans, education, business.industry, Proportional hazards model, HODGKINS-LYMPHOMA, Cancer, LONG-TERM SURVIVAL, 5-YEAR SURVIVORS, medicine.disease, Survival Analysis, Cancer registry, Subsequent malignant neoplasm, Radiation therapy, RADIATION, Neoplasms, Second Primary/epidemiology, business
وصف الملف: text/plain; application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::093a364278ecd06200a4e6de4329c2d0Test
https://pure.eur.nl/en/publications/94f8e789-071e-415f-aad3-136325cedb08Test -
5
المؤلفون: Dóra Körmendiné Farkas, Deirdre Cronin-Fenton, Mette Nørgaard, Lidia Schapira, Mark R. Cullen, Jens Sundbøll, Henrik Toft Sørensen, Suzanne Tamang, Kasper Adelborg
المصدر: Sundbøll, J, Farkas, D K, Adelborg, K, Schapira, L, Tamang, S, Nørgaard, M, Cullen, M R, Cronin-Fenton, D & Sørensen, H T 2020, ' Risk of primary urological and genital cancers following incident breast cancer : a Danish population-based cohort study ', Breast Cancer Research and Treatment, vol. 184, no. 3, pp. 825-837 . https://doi.org/10.1007/s10549-020-05879-wTest
مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Denmark, Population, Breast Neoplasms, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Risk Factors, Uterine cancer, Internal medicine, medicine, Humans, Genitalia, Registries, education, Cervical cancer, education.field_of_study, business.industry, Breast Neoplasms/epidemiology, Incidence, Incidence (epidemiology), Neoplasms, Second Primary, Middle Aged, medicine.disease, Denmark/epidemiology, 030104 developmental biology, 030220 oncology & carcinogenesis, Female breast cancer, Cohort, Neoplasms, Second Primary/epidemiology, Female, business, Ovarian cancer, Cohort study, Kidney cancer, Second primary cancer
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f88ad7ddbc9d23376ef0cacbc2c2ca75Test
https://pure.au.dk/portal/da/publications/risk-ofTest-primary -urological-and-genital-cancers-following-incident-breast-cancer(396bf2b8-1524-4741-8a69-1bdff840dfbd).html -
6
المؤلفون: Cirt-Fr Principal Investigators, Jean-Pierre Pelage, Charles Mastier, Valérie Vilgrain, Christian Sengel, Maxime Ronot, Michel Greget, Lambros Tselikas, Bruno Sangro, Bora Peynircioglu, Nathalie Kaufmann, José Ignacio Bilbao, María Urdániz, Thomas Helmberger, Dirk Arnold, Olivier Pellerin, Geert Maleux, Antoine Bouvier, Niklaus Schaefer, Romaric Loffroy
المساهمون: CIRT-FR Principal Investigators, Piana, G., Frandon, J., Tasu, J.P., Kobeiter, H.
المصدر: Cardiovascular and Interventional Radiology
Cardiovascular and interventional radiology, vol. 44, no. 1, pp. 36-49مصطلحات موضوعية: Male, SIR-Spheres, Yttrium-90, Cardiac & Cardiovascular Systems, Tare weight, medicine.medical_treatment, 0302 clinical medicine, MICROSPHERES, Quality of life, HEPATOCELLULAR-CARCINOMA, Yttrium Radioisotopes, SIRT, Reimbursement, Incidence, Liver Neoplasms, Radiology, Nuclear Medicine & Medical Imaging, Neoplasms, Second Primary, Embolization, Therapeutic, EORTC, 030220 oncology & carcinogenesis, Cohort, 030211 gastroenterology & hepatology, Female, TRIAL, France, Cardiology and Cardiovascular Medicine, Life Sciences & Biomedicine, medicine.medical_specialty, Carcinoma, Hepatocellular, Transarterial radioembolization, SIR-spheres, 03 medical and health sciences, Carcinoma, Hepatocellular/diagnosis, Carcinoma, Hepatocellular/epidemiology, Carcinoma, Hepatocellular/therapy, Embolization, Therapeutic/methods, France/epidemiology, Humans, Liver Neoplasms/diagnosis, Liver Neoplasms/epidemiology, Liver Neoplasms/therapy, Neoplasms, Second Primary/diagnosis, Neoplasms, Second Primary/epidemiology, Neoplasms, Second Primary/therapy, Quality of Life, Yttrium Radioisotopes/therapeutic use, Interim analysis, Radioembolization, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Clinical Investigation, Adverse effect, Science & Technology, INTERNAL RADIATION-THERAPY, business.industry, SORAFENIB, Cardiovascular System & Cardiology, Observational study, business
وصف الملف: Print-Electronic; application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71ee18c72cc9ba56091bfd26a6c6d85fTest
https://lirias.kuleuven.be/handle/20.500.12942/705671Test -
7
المؤلفون: Mark Tulchinsky, Einat Slonimsky
المصدر: Current Pharmaceutical Design
مصطلحات موضوعية: medicine.medical_specialty, medicine.medical_treatment, Remnant ablation, Thyroglobulin, Article, 030218 nuclear medicine & medical imaging, Iodine Radioisotopes, 03 medical and health sciences, 0302 clinical medicine, Drug Discovery, medicine, Humans, Thyroid Neoplasms, Thyroid cancer, Retrospective Studies, Pharmacology, Total thyroidectomy, business.industry, Thyroid, Iodine Radioisotopes, adverse effects/therapeutic use, thyroid neoplasms/th [therapy], Adenocarcinoma, Follicular, radiotherapy, Carcinoma, Papillary, radiotherapy, Thyroid Neoplasms/epidemiology, radiotherapy, Neoplasms, Radiation-Induced, epidemiology/etiology, Neoplasms, Second Primary, epidemiology/etiology, Iodides, medicine.disease, Occult, Iodine Radioisotopes, therapeutic use, medicine.anatomical_structure, Current practice, 030220 oncology & carcinogenesis, Radiology, Radioactive iodine, Neoplasm Recurrence, Local, business
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::564ead09cf104a21460ce50bb3ee01d5Test
https://pubmed.ncbi.nlm.nih.gov/32503402Test -
8
المؤلفون: DCOG-LATER Study Group
مصطلحات موضوعية: Male, Adult, Cancer Research, Survival, Epidemiology, Breast Neoplasms/epidemiology, Long-term complications, Survival Analysis, Childhood cancer survivors, Subsequent malignant neoplasm, Melanoma/epidemiology, Cohort Studies, Cancer Survivors, Oncology, Journal Article, Humans, Skin Neoplasms/epidemiology, Female, Neoplasms, Second Primary/epidemiology, Sarcoma/epidemiology, Child, Netherlands
وصف الملف: image/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od_____10691::52bbe16a57a7ede1a806bd80afbf7316Test
https://dspace.library.uu.nl/handle/1874/392061Test -
9دورية أكاديمية
المؤلفون: Moe, P J
المصدر: Medicinsk Årbog. :105
-
10
المؤلفون: Antonela Samardžić, Zinaida Perić, Ranka Serventi-Seiwerth, Lana Desnica, Radovan Vrhovac, Nadira Duraković
المصدر: Liječnički vjesnik
Volume 141
Issue 5-6مصطلحات موضوعية: transplantacija krvotvornih matičnih stanica, transplantacija koštane srži, alogena transplantacija, dugoročni negativni učinci, dugoročno preživljenje, HEMATOPOIETIC STEM CELL TRANSPLANTATION – adverse effects, statistics and numerical data, CARDIOVASCULAR DISEASES – epidemiology, etiology, ENDOCRINE SYSTEM DISEASES – epidemiology, etiology, NEOPLASMS, SECOND PRIMARY – epidemiology, etiology, GRAFT VS HOST DISEASE – epidemiology, etiology, CHRONIC DISEASE, SURVIVORS, QUALITY OF LIFE, TRANSPLANTATION, HOMOLOGOUS, TIME FACTORS, RETROSPECTIVE STUDIES, TRANSPLANTACIJA KRVOTVORNIH MATIČNIH STANICA – neželjeni učinci, statistički podatci, KARDIOVASKULARNE BOLESTI – epidemiologija, etiologija, ENDOKRINE BOLESTI – epidemiologija, etiologija, SEKUNDARNI TUMORI – epidemiologija, etiologija, BOLEST PRESATKA PROTIV PRIMATELJA – epidemiologija, etiologija, KRONIČNA BOLEST, PREŽIVJELI, KVALITETA ŽIVOTA, ALOGENA TRANSPLANTACIJA, VREMENSKI ČIMBENICI, RETROSPEKTIVNE STUDIJE
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::76f55f3e99a92f91a39d3a81b1e5190eTest
https://doi.org/10.26800/lv-141-5-6-17Test